Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the...

Area of Science:

• Cardiology
• Interventional Cardiology
• Pharmacology

Background:

• Small myocardial infarctions post-percutaneous coronary intervention (PCI) are linked to increased cardiac event risk.
• Observational studies suggest statins may mitigate procedural myocardial injury.
• This randomized study aimed to validate the hypothesis that statins reduce PCI-related myocardial injury.

Purpose of the Study:

• To evaluate the efficacy of atorvastatin pretreatment in preventing myocardial injury during elective coronary intervention.
• To compare the incidence of myocardial injury markers between patients receiving atorvastatin and placebo.

Main Methods:

• A randomized controlled trial involving 153 patients with stable angina without prior statin use.
• Patients received either atorvastatin (40 mg/d) or placebo for 7 days before elective coronary intervention.
• Cardiac biomarkers (creatine kinase-MB, troponin I, myoglobin) were measured pre- and post-procedure.

Main Results:

• Significantly lower detection of myocardial injury markers (creatine kinase-MB, troponin I, myoglobin) in the atorvastatin group (12-22%) compared to placebo (35-51%).
• Myocardial infarction incidence was lower in the atorvastatin group (5%) versus placebo (18%).
• Postprocedural peak levels of all measured cardiac biomarkers were significantly reduced with atorvastatin pretreatment.

Conclusions:

• Pretreatment with atorvastatin (40 mg/d for 7 days) effectively reduces procedural myocardial injury in elective coronary intervention.
• These findings suggest a potential shift in practice regarding the use of statins before percutaneous revascularization.
• Atorvastatin demonstrates a protective effect against myocardial damage associated with coronary interventions.